**Insmed (INSM) shares rose 5.5% in the latest trading session, closing at $153.32.** This increase is linked to a significant rise in trading volume, contrasting with a prior 2.7% decline over the last month. The surge follows positive results from a late-stage study by United Therapeutics, which showed that Tyvaso improved absolute forced vital capacity (FVC) by 130.1 mL in patients with idiopathic pulmonary fibrosis (IPF) over 52 weeks compared to a placebo.
Insmed is developing a similar treatment, the treprostinil palmitil inhalation powder (TPIP), which allows for once-daily dosing versus multiple doses of Tyvaso. The company plans to initiate a late-stage study on TPIP in IPF in the second half of 2026. Insmed is anticipated to report a quarterly loss of $1.00 per share, reflecting a year-over-year increase of 29.6%, with revenues expected to reach $299.57 million, up 222.7% from the previous year.
